Continuous glucose monitors (CGMs) have quietly crossed from medical necessity into the wellness world, creating a regulatory gray zone that's reshaping how we think about health tracking. Once prescribed exclusively to people with diabetes to manage insulin and prevent dangerous blood sugar dips, these sensors are now available without a prescription for about $100 a month to anyone wanting to optimize their metabolic health and weight loss. As startups build apps around this data, the line between medical device and wellness product has become blurry—and the FDA is now stepping in to clarify where that line should be. How Did Glucose Monitors Become a Wellness Trend? For years, continuous glucose monitors lived in a gray area. While most CGMs were found on the arms of people with diabetes, helping them dose insulin and catch overnight glucose dips, a small batch of companies quietly began prescribing them off-label to users interested in metabolic health and weight loss. The game changed last summer when both Dexcom and Abbott began selling continuous glucose monitors without a prescription, making real-time blood glucose monitoring accessible to any adult—diabetes or not. This shift opened the door for a new category of health apps. Companies like Signos, Nutrisense, and Levels started selling Dexcom's Stelo CGM directly to consumers, pairing the sensors with apps designed to help users maintain healthy weight and optimize their metabolism. The tension between wellness and medicine had reached a breaking point. Where Is the FDA Drawing the Line? The regulatory response has been uneven. Signos, which is backed by Dexcom Ventures, announced that its app received FDA clearance as a medical device to help users maintain healthy weight when used with Dexcom's Stelo CGM. However, competitors like Nutrisense and Levels continue to present their apps as general wellness products, not medical devices, even though they're analyzing the same glucose data. This creates a patchwork where some companies seek FDA approval and others don't—both selling essentially the same product to the same audience. The distinction matters because FDA-cleared medical devices face stricter requirements around safety, effectiveness, and labeling. Apps presented as wellness tools face fewer regulatory hurdles but also make fewer medical claims. Why Should You Care About This Distinction? The difference between a medical device and a wellness tool affects what you can expect from the product. A medical device cleared by the FDA has been evaluated for safety and effectiveness at making specific health claims. A wellness app, by contrast, is not making medical claims and therefore hasn't undergone the same scrutiny. If you're considering using a CGM with an app to manage your weight or metabolic health, understanding whether that app is FDA-cleared matters for knowing what evidence supports its claims. The regulatory uncertainty also affects how these products are reimbursed. Insurance coverage for CGMs has traditionally been tied to diabetes diagnosis. As these devices move into the wellness space, questions about insurance coverage and whether they should be covered remain unanswered. Some users may find themselves paying out-of-pocket for devices that others get covered by insurance, depending on their health status and insurance plan. Steps to Understanding CGM Apps and Medical Claims - Check FDA Status: Before purchasing a CGM app, search the FDA's database to see if the app has received medical device clearance. Apps with clearance will explicitly state this in their marketing materials and on their websites. - Review the Claims: Look at what the app promises to do. If it claims to diagnose, treat, or prevent disease, it should be FDA-cleared. If it only tracks data and provides general wellness suggestions, it may not require clearance. - Verify Insurance Coverage: Contact your insurance provider to ask whether they cover CGM devices and apps. Coverage often depends on whether you have a diabetes diagnosis or other qualifying condition. - Understand the Data: Ask the company what evidence supports the app's recommendations. Medical devices should cite clinical studies; wellness apps may rely on general health principles without specific clinical validation. What Does This Mean for the Future of Health Monitoring? The CGM story reflects a broader tension in digital health: as consumer technology becomes more sophisticated, the line between medical care and personal wellness blurs. Smartwatches, fitness trackers, and health apps already occupy this gray zone, and continuous glucose monitors are just the latest example. Remote patient monitoring devices are increasingly becoming a structural pillar of healthcare delivery. The World Health Organization has identified remote patient monitoring as one of the healthcare delivery models with the potential to improve global health outcomes at scale. By enabling clinicians to collect real-time data from patients outside traditional facilities, remote monitoring supports earlier intervention, better disease management, and improved long-term outcomes. The devices currently transforming healthcare include blood pressure cuffs, glucose monitors, pulse oximeters, electrocardiogram (ECG) patches, peak flow meters, smartwatches, thermometers, wireless scales, smart inhalers, and remote maternal monitoring devices. Some require patients to take measurements manually, while others operate continuously, sending data directly to electronic health records. As these technologies proliferate, the FDA's approach to CGMs may set a precedent for how other consumer health devices are regulated. Will the agency require FDA clearance for all health apps that make claims about disease prevention or management? Or will it allow a two-tier system where some apps are medical devices and others are wellness tools? The answer will shape the future of digital health for years to come. For now, the glucose monitor divide remains unresolved. Consumers shopping for CGM apps should understand that not all products claiming to improve metabolic health have the same level of regulatory oversight. As the market evolves, expect more clarity—and more debate—about where the line between medicine and wellness should be drawn.
